220 POSTER Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo

2008 ◽  
Vol 6 (12) ◽  
pp. 69-70 ◽  
Author(s):  
D. Sampath ◽  
M. Belvin ◽  
J. Guan ◽  
K. Edgar ◽  
J. Wallin ◽  
...  
Keyword(s):  
Human Cancer ◽  
Standard Of Care ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Cancer Models

scholarly journals GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

2012 ◽  
Vol 18 (14) ◽  
pp. 3901-3911 ◽  
Author(s):  
Jeffrey J. Wallin ◽  
Jane Guan ◽  
Wei Wei Prior ◽  
Leslie B. Lee ◽  
Leanne Berry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Human Breast Cancer ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Human Breast ◽  
Cancer Models

scholarly journals Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models

2004 ◽  
Vol 10 (4) ◽  
pp. 1263-1273 ◽  
Author(s):  
Zhuo Zhang ◽  
Hui Wang ◽  
Gautam Prasad ◽  
Mao Li ◽  
Dong Yu ◽  
...  
Keyword(s):  
Human Cancer ◽  
Cancer Models

Cancer modeling meets human organoid technology

Science ◽  
2019 ◽  
Vol 364 (6444) ◽  
pp. 952-955 ◽  
Author(s):  
David Tuveson ◽  
Hans Clevers
Keyword(s):  
Human Cancer ◽  
Three Dimensional ◽  
Gene Modification ◽  
Current State ◽  
Functional Aspects ◽  
Cancer Models ◽  
Immune Oncology ◽  
Gene Alterations

Organoids are microscopic self-organizing, three-dimensional structures that are grown from stem cells in vitro. They recapitulate many structural and functional aspects of their in vivo counterpart organs. This versatile technology has led to the development of many novel human cancer models. It is now possible to create indefinitely expanding organoids starting from tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer through the introduction of any combination of cancer gene alterations to normal organoids. When combined with immune cells and fibroblasts, tumor organoids become models for the cancer microenvironment enabling immune-oncology applications. Emerging evidence indicates that organoids can be used to accurately predict drug responses in a personalized treatment setting. Here, we review the current state and future prospects of the rapidly evolving tumor organoid field.

scholarly journals 596 Armed myxoma virus demonstrates therapeutic activity in xenograft models

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A631-A631
Author(s):  
Lino Torres-Dominguez ◽  
Lina Franco ◽  
Mario Abrantes ◽  
Benjamin Walker ◽  
Zachary Tacner ◽  
...  
Keyword(s):  
Cell Lines ◽  
Cancer Cell ◽  
Human Cancer ◽  
Cancer Cell Lines ◽  
Myxoma Virus ◽  
Human Cancer Cell Lines ◽  
Cancer Models ◽  
Oncolytic Activity

BackgroundOncolytic Viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system. This represents a promising therapeutic option for cancer patients that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins making it an excellent oncolytic virus for introduction of immunomodulatory proteins.MethodsThe current work describes the in vitro oncolytic activity and transgene production capability in human cancer cell lines, and in vivo activity of armed myxoma viruses in xenograft human cancer models.ResultsArmed Myxoma viruses demonstrate transgene production and oncolytic activity in multiple human cancer cell lines in vitro and in vivoConclusionsArmed Myxoma viruses present a novel oncolytic viral therapy with ability to modulate immune responses in human cancer modelsEthics ApprovalThis study was approved by OncoMyx Therapeutics and the TD2 IACUC

The truncated somatostatin receptor sst5TMD4 stimulates the production of pro-angiogenic factors in in vitro and in vivo breast cancer models

2014 ◽  
Author(s):  
Raul M Luque ◽  
Mario Duran-Prado ◽  
David Rincon-Fernandez ◽  
Marta Hergueta-Redondo ◽  
Michael D Culler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Somatostatin Receptor ◽  
Angiogenic Factors ◽  
Cancer Models

Opiophobia in Cancer Biology- Justified? - The Role of Perioperative Use of Opioids in Cancer Recurrence

2019 ◽  
Vol 25 (28) ◽  
pp. 3020-3027 ◽  
Author(s):  
Mir W. Sekandarzad ◽  
Chris Doornebal ◽  
Markus W. Hollmann
Keyword(s):  
Pain Management ◽  
Cancer Biology ◽  
Tumor Biology ◽  
Cancer Recurrence ◽  
Standard Of Care ◽  
Cancer Surgery ◽  
Perioperative Pain Management ◽  
Tumor Growth And Metastasis

: Opioids remain the standard of care in the provision of analgesia in the patient undergoing cancer surgery preoperatively. : The effects of opioids on tumor growth and metastasis have been discussed for many years. In recent years their use as part of the perioperative pain management bundle in the patients undergoing cancer surgery has been thought to promote cancer recurrence and metastasis. : This narrative review highlights earlier and more recent in vitro, in vivo and human retrospective studies that yield conflicting results as to the immune-modulatory effects of morphine on tumor biology. The article examines and explains the discrepancies with regards to the seemingly opposite results of morphine in the tumor milieu. The results of both, earlier studies that demonstrated procarcinogenic effects versus the data of more recent refined rodent studies that yielded neutral or even anti-carcinogenic effects are presented here. : Until the results of prospective randomized controlled trials are available to clarify this important question, it is currently not warranted to support opiophobia and opioids continue to constitute a pivotal role in the pain management of cancer patients.

scholarly journals A New Smoothened Antagonist Bearing the Purine Scaffold Shows Antitumour Activity In Vitro and In Vivo

2021 ◽  
Vol 22 (16) ◽  
pp. 8372
Author(s):  
Ana María Zárate ◽  
Christian Espinosa-Bustos ◽  
Simón Guerrero ◽  
Angélica Fierro ◽  
Felipe Oyarzún-Ampuero ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Human Cancer ◽  
Antitumour Activity ◽  
Anticancer Compounds ◽  
Human Cancer Cells ◽  
Cycle Arrest ◽  
Apoptosis Inducer ◽  
Purine Ring

The Smoothened (SMO) receptor is the most druggable target in the Hedgehog (HH) pathway for anticancer compounds. However, SMO antagonists such as vismodegib rapidly develop drug resistance. In this study, new SMO antagonists having the versatile purine ring as a scaffold were designed, synthesised, and biologically tested to provide an insight to their mechanism of action. Compound 4s was the most active and the best inhibitor of cell growth and selectively cytotoxic to cancer cells. 4s induced cell cycle arrest, apoptosis, a reduction in colony formation and downregulation of PTCH and GLI1 expression. BODIPY-cyclopamine displacement assays confirmed 4s is a SMO antagonist. In vivo, 4s strongly inhibited tumour relapse and metastasis of melanoma cells in mice. In vitro, 4s was more efficient than vismodegib to induce apoptosis in human cancer cells and that might be attributed to its dual ability to function as a SMO antagonist and apoptosis inducer.

Sign in / Sign up

Export Citation Format

Share Document